Intuitive Surgical, Inc. — Q2 2023 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2023; comparisons are with the corresponding 2022 periods. Intuitive develops and sells da Vinci surgical systems and the Ion endoluminal system, with recurring revenue from instruments, accessories, services, and leases. Figures are unaudited.
Financial performance
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $1.756bn (+15%) | $1.522bn | $3.452bn (+15%) | $3.010bn |
| Gross profit / margin | $1.172bn / 66.7% | $1.023bn / 67.2% | $2.285bn / 66.2% | $2.033bn / 67.5% |
| Operating income | $463.2m (+16%) | $397.6m | $850.8m (+6%) | $805.7m |
| Net income attributable to Intuitive | $420.8m (+37%) | $307.8m | $776.1m (+15%) | $673.4m |
| Diluted EPS | $1.18 | $0.85 | $2.18 | $1.84 |
- Q2 revenue growth was led by instruments and accessories, up 20% to $1.076bn, supported by da Vinci procedure growth of about 22%. Service revenue rose 14% to $287m; systems revenue rose 5% to $393m.
- Recurring revenue was $1.486bn in Q2, 85% of total revenue, compared with $1.240bn, or 81%, a year earlier.
- Q2 gross margin edged lower. Management cited lower system average selling prices (ASP), product mix, and higher component costs; service margin improved with repair-volume leverage and operating efficiencies.
- Interest and other income, net, was $36.0m in Q2 and $70.2m for the first half, versus $9.3m and $3.6m, respectively, in 2022. Higher interest income was a principal driver.
Cash, liquidity, and capital
- At June 30, cash and cash equivalents were $3.435bn, short-term investments $2.364bn, and long-term investments $1.333bn, totaling $7.132bn in cash, cash equivalents, and investments. Total current assets were $8.032bn and current liabilities $1.538bn.
- Total liabilities were $1.944bn; the balance sheet does not present a separate borrowing or debt balance.
- For the six months, operating cash flow was $1.037bn, investing cash flow was $1.131bn, and financing cash outflow was $318m. Capital expenditures were $372m. Inventory increased by $289m, partly to support growth and mitigate supply risks.
- Intuitive repurchased $350m of stock in the first half; there were no repurchases in Q2. Approximately $1.1bn remained authorized at June 30.
Operating trends and changes versus prior year
- Da Vinci procedures increased about 22% in Q2 and 24% in the first half. Ion procedures increased 145% in Q2 to approximately 12,700.
- Q2 da Vinci placements rose to 331 from 279; the installed base reached approximately 8,042, up 13% year over year. Utilization, measured as procedures per system per year, increased 9%. Ion placements were 59, and its installed base reached approximately 435.
- OUS da Vinci procedure growth was about 28% in Q2 versus 19% in the U.S.; management reported strength in China, Japan, Germany, and the UK. Comparisons were affected by COVID-19 disruptions in the 2022 period, including China.
- System ASP, excluding operating/usage-based leases and Ion, declined to about $1.39m in Q2 from $1.50m; management cited unfavorable mix, foreign exchange, and higher discounts. A greater share of placements under operating leases also affected recognized systems revenue.
- Operating expenses increased: Q2 SG&A rose 11% to $464m and R&D rose 18% to $244m. Higher headcount, compensation, marketing, training, travel, and broader development programs contributed.
Outlook, risks, and unusual items
- Management expects 2023 capital expenditures of $800m–$1.0bn, over half for facilities, funded from operating cash flow. It expects substantial and increasing R&D investment. The filing provides no specific revenue or procedure-growth guidance.
- Management expects hospital capital spending, particularly in the U.S., to remain pressured amid staffing constraints, inflation, higher interest rates, and tighter budgets; it cited a softer U.S. capital pipeline and potential longer sales cycles and pricing pressure.
- Supply constraints for semiconductors and other components and elevated input costs remain risks, although conditions showed signs of improvement in the first half. Prolonged shortages could constrain supply or defer procedures. COVID-19 had no significant Q2 disruption, but future effects remain uncertain.
- Other material risks include competition, regulatory and product-quality requirements, China procedure-pricing limits and uncertain equipment quotas, hospital customer credit risk, foreign exchange and investment-market volatility, and cybersecurity threats.
- Legal matters include product-liability claims, for which the company says possible losses above recorded amounts cannot currently be estimated; antitrust litigation with hearings scheduled for September 2023; and patent disputes. A jury awarded Rex Medical $10m in 2022; Intuitive intends to appeal and says it does not expect the matter to be material. Ethicon may seek rehearing in a patent appeal; an adverse outcome could affect U.S. imports of certain SureForm products.
- The Q2 effective tax rate was 14.7%, versus 22.9% a year earlier, primarily reflecting employee-equity tax benefits and a more favorable earnings mix. The six-month rates were 14.6% and 15.6%. Equity-award tax benefits can make the rate volatile.
- Unrealized losses on available-for-sale debt securities reflected interest-rate increases; management said it did not intend to sell the securities and did not expect to realize those losses. Disclosure controls were assessed as effective.
Most important facts for investors to verify
- Whether da Vinci procedure growth and utilization persist after accounting for COVID-era comparison effects, and whether the slower Q2 growth in U.S. bariatric procedures continues.
- How the shift toward operating and usage-based leases, lower ASPs, discounts, and product mix affect systems revenue, margins, and cash generation.
- Whether hospital budget pressure, supply constraints, component inflation, and China pricing or quota developments alter placements and procedure growth.
- Execution against the $800m–$1.0bn capital-spending outlook and continued R&D investment, alongside inventory and working-capital needs.
- Developments in product-liability, antitrust, and patent cases, including the potential range of losses where the filing says it cannot be estimated.